What does a raised PSA actually mean?

What PSA actually is

PSA is a 33-kilodalton glycoprotein of the kallikrein gene family (KLK3), functioning as a serine protease that liquefies seminal coagulum after ejaculation^[1]. It was isolated from human seminal plasma by Hara in 1971 and from serum by Wang and colleagues in 1979^[1]. The U.S. Food and Drug Administration approved serum PSA in 1986 for monitoring known prostate cancer, and in 1994 for screening in combination with digital rectal examination (DRE)^[2].

Although produced in small quantities by some non-prostatic tissues (notably periurethral and perianal glands), PSA is functionally prostate-specific in clinically relevant concentrations. Anything that disrupts the architecture of the prostate — cancer, but also benign enlargement, inflammation, infection, or mechanical disturbance — increases PSA leakage into the bloodstream. PSA is therefore a marker of prostatic activity, not specifically of prostate cancer^[3].

What counts as a "raised" PSA — age-adjusted reference ranges

The traditional cutoff of 4.0 ng/mL was established by Catalona and colleagues in 1991^[3]. Below this value, biopsy was considered unwarranted; above it, biopsy was generally recommended. This single threshold has well-documented limitations: in the Prostate Cancer Prevention Trial, 15.2 percent of men with PSA ≤ 4.0 ng/mL still had biopsy-detectable cancer, including 14.9 percent who had clinically significant disease (Gleason ≥ 7)^[4].

Because the prostate enlarges naturally with age, fixed thresholds over-investigate older men and under-investigate younger men. Oesterling and colleagues established the age-specific reference ranges still widely used today^[5]:

The American Urological Association notes that men of African descent generally have higher baseline PSA values and a higher incidence of clinically significant prostate cancer, and recommends that clinicians take ethnicity into account when interpreting results^[6]. The European Association of Urology recommends a baseline PSA at age 40-45 for risk stratification in men with a family history of prostate cancer or known BRCA1/BRCA2 mutations^[7].

It is important to understand that these are reference ranges, not diagnostic thresholds. A PSA above the age-adjusted upper limit does not mean cancer; it means further evaluation is appropriate.

Why PSA can be raised (and why most raised PSAs are not cancer)

Multiple benign conditions and transient factors can elevate PSA. The most common causes:

• Benign prostatic hyperplasia (BPH) — the dominant non-cancer cause in men over 50. PSA correlates with total prostate volume at approximately 0.3 ng/mL per gram of prostate tissue^[8]. A man with a 60 g prostate may have a baseline PSA around 4 ng/mL without any pathology.
• Prostatitis — acute bacterial prostatitis can elevate PSA dramatically, sometimes above 50 ng/mL, and takes 4-8 weeks to normalise after appropriate antibiotic treatment^[9]. Chronic prostatitis produces more modest elevations.
• Recent ejaculation — Tchetgen and colleagues showed that ejaculation transiently elevates PSA by up to 1.0 ng/mL, with values returning to baseline by approximately 48 hours^[10]. Men are typically advised to abstain for 48 hours before a PSA test.
• Long-distance cycling — Mejak and colleagues showed in a 2013 PLOS ONE study that cycling 50 miles transiently raises PSA, with mean elevation of approximately 9.5 percent at 5 minutes post-ride^[11]; most guidelines recommend avoiding strenuous cycling for 48 hours before testing.
• Digital rectal examination (DRE) — produces clinically insignificant PSA elevation in most studies (mean change less than 0.4 ng/mL)^[12]. A DRE on the same day as a planned PSA draw does not invalidate the test.
• Prostate biopsy — produces large transient elevation; PSA can take 4-6 weeks to return to baseline and should not be repeated within that window^[13].
• Urinary tract infection — can elevate PSA; the test should be deferred until the infection has resolved^[9].
• 5-alpha-reductase inhibitors (finasteride, dutasteride) — these BPH medications halve PSA values within approximately 6 months of starting therapy. Men on these drugs require the measured PSA to be doubled for accurate interpretation^[14].

What if my PSA is rising over time? — PSA velocity and doubling time

A single raised PSA reading is one data point. The pattern of PSA change over time — its velocity and doubling time — gives a much richer signal than any single value.

PSA velocity is the rate of PSA rise, typically expressed in ng/mL per year. Carter and colleagues established the foundational threshold in a 1992 JAMA paper: a PSA velocity greater than 0.75 ng/mL per year in men with baseline PSA below 4 raised concern for cancer, with specificity of 90 percent^[17]. Subsequent analyses have refined this — Carter et al. (J Natl Cancer Inst, 2006) suggested even lower thresholds (>0.35 ng/mL/year) may be clinically meaningful in younger men with low baseline PSA^[27]. Modern guidelines treat PSA velocity as an adjunct to other metrics rather than a standalone trigger, because day-to-day biological variation can produce misleadingly high velocity if too few measurements are used. Most clinicians require at least three PSA values over 18-24 months before placing weight on velocity.

PSA doubling time is the time taken for PSA to double, typically reported in months. It is most clinically informative after a cancer diagnosis — specifically in biochemical recurrence following primary treatment. Pound and colleagues (JAMA, 1999) demonstrated that PSA doubling time after radical prostatectomy is one of the strongest predictors of distant metastasis: doubling time below 10 months is associated with substantially higher risk of metastasis and prostate-cancer-specific mortality, while doubling time above 15 months is associated with much slower-progressing disease^[28]. In an untreated raised-PSA context (no confirmed cancer), doubling time is less directly clinically useful than velocity but is sometimes calculated for surveillance.

What happens next — the diagnostic pathway

A raised PSA on a single test is not enough to trigger biopsy. The contemporary diagnostic pathway, supported by current European Association of Urology and American Urological Association guidelines, is structured as follows^[6][7]:

Step 1: Confirm with a repeat PSA. A repeat PSA at 4-8 weeks (after controlling for transient causes — abstaining from ejaculation for 48 hours, no recent UTI, no recent prostate manipulation) rules out laboratory variation and transient elevations^[6].

Step 2: Adjunct PSA-based metrics. Three derived metrics improve specificity:

• Free-to-total PSA ratio — most PSA in blood is bound to alpha-1-antichymotrypsin; cancer cells produce relatively more bound PSA. A free PSA ratio below 25 percent raises concern; below 10 percent is strongly suggestive of cancer (Catalona 1998)^[15].
• PSA density — PSA divided by prostate volume (from transrectal ultrasound or MRI). A density above 0.15 ng/mL/cc increases the likelihood of clinically significant cancer^[16].
• PSA velocity — as described in the section above; a velocity above 0.75 ng/mL/year in men with baseline PSA below 4 raises concern^[17].

Step 3: Multiparametric MRI of the prostate. The PROMIS study (Ahmed et al., Lancet 2017) demonstrated that multiparametric MRI (mpMRI) before biopsy has higher sensitivity (93 percent) than standard transrectal ultrasound-guided biopsy (48 percent) for clinically significant cancer^[18]. The PRECISION trial (Kasivisvanathan et al., NEJM 2018) confirmed that an MRI-first pathway detects more clinically significant cancers (38 percent vs 26 percent) while reducing detection of clinically insignificant disease (9 percent vs 22 percent) and avoiding biopsy in 28 percent of men^[19]. mpMRI before biopsy is now the contemporary standard.

Step 4: PI-RADS scoring and targeted biopsy. Lesions identified on mpMRI are scored using the Prostate Imaging Reporting and Data System (PI-RADS) version 2.1^[20]. PI-RADS 3-5 lesions trigger targeted biopsy (typically MRI-ultrasound fusion biopsy or in-bore MRI-guided biopsy).

Step 5: Additional molecular adjuncts where appropriate. In selected cases, urine-based or blood-based molecular tests can refine biopsy decisions — including the 4Kscore, SelectMDx, ExoDx Prostate IntelliScore, and MyProstateScore^[21]. These are typically used when initial workup is equivocal.

Dr. Ishita B. Sen, MD · Director & Chief, Nuclear Medicine, FMRI

When PSMA PET-CT enters the picture

PSMA PET-CT is a powerful nuclear medicine imaging modality that targets prostate-specific membrane antigen — a protein highly expressed on prostate cancer cells. The U.S. FDA approved Gallium-68 PSMA-11 in December 2020 and Fluorine-18 piflufolastat (Pylarify) in May 2021 for clinical use^[22]. It is important to understand where this scan does — and does not — fit in the raised-PSA pathway.

PSMA PET-CT is used for:

• Initial staging of newly diagnosed unfavourable-intermediate-risk and high-risk prostate cancer. The proPSMA trial (Hofman et al., Lancet 2020) demonstrated that PSMA PET-CT had 27 percent higher accuracy than conventional imaging — 92 percent versus 65 percent — for detecting metastatic disease^[23]. PSMA PET-CT changed management in 28 percent of patients in the trial.
• Biochemical recurrence — rising PSA after definitive primary treatment. PSMA PET-CT detects sites of recurrence at substantially lower PSA values than older imaging^[24].
• Treatment-eligibility assessment — particularly for Lu-177 PSMA radioligand therapy in advanced disease^[25].

PSMA PET-CT is not used for:

• The initial workup of a raised PSA in a man without confirmed prostate cancer. Multiparametric MRI of the prostate is the appropriate first-line imaging in this context^[6][7].

If you have been told you have a raised PSA but have not yet had a biopsy or formal cancer diagnosis, your next imaging study should be a multiparametric MRI of the prostate, not a PSMA PET-CT. For a broader picture of prostate cancer staging, treatment by stage, and where nuclear medicine fits, see our pillar guide: An in-depth look at prostate cancer.

Can you lower a raised PSA? What actually works (and what does not)

The honest answer to "can I lower my PSA?" is: it depends entirely on why the PSA is raised. Lowering a PSA that is raised because of a treatable benign condition is reasonable and useful. Lowering a PSA that is raised because of cancer, without addressing the cancer, is harmful — because it masks the underlying disease and can delay diagnosis.

Interventions with evidence — and how they actually work:

• 5-alpha-reductase inhibitors (finasteride, dutasteride) halve PSA values within approximately 6 months of starting therapy (Etzioni et al., J Urol 2005)^[14]. These drugs are commonly used for BPH and male-pattern hair loss. Crucially: they do not "treat" a raised PSA — they suppress it. Men on these drugs require the measured PSA to be doubled for accurate interpretation. The Prostate Cancer Prevention Trial (Thompson et al., NEJM 2003) demonstrated that finasteride reduced overall prostate cancer incidence by 24.8 percent but with a possible association with higher-grade tumours in detected cases^[29].
• Antibiotic treatment of bacterial prostatitis can dramatically reduce a PSA elevated by infection. Nadler et al. (J Urol 1995) showed that resolving prostatic inflammation produces PSA reductions, sometimes from values above 50 ng/mL back to normal range over 4-8 weeks^[9]. Empirical antibiotic trials in the absence of confirmed prostatitis are not recommended.
• Treating a urinary tract infection allows a misleadingly elevated PSA to normalise; a PSA test should be deferred until the infection has resolved^[9].
• Allowing time after recent ejaculation, cycling, or prostate manipulation — abstain from ejaculation for 48 hours and avoid strenuous cycling for 48 hours before retesting; allow 4-6 weeks after a prostate biopsy^[10][11][13].

Interventions with weak or no high-quality evidence:

• Saw palmetto (Serenoa repens) — multiple randomised trials have shown no clinically meaningful PSA reduction. The STEP trial (Bent et al., NEJM 2006) was a 14-month placebo-controlled trial of saw palmetto in men with BPH symptoms and found no significant effect on PSA, urinary symptoms, or prostate volume^[30]. The CAMUS trial (Barry et al., JAMA 2011) confirmed this finding at higher doses^[31].
• Lycopene, pomegranate, green tea, selenium, vitamin E, zinc — small studies have suggested possible effects, but the Selenium and Vitamin E Cancer Prevention Trial (SELECT; Klein et al., JAMA 2011) showed selenium and vitamin E did not reduce prostate cancer risk, and vitamin E was associated with a small increase in risk^[32]. Pomegranate juice studies (Pantuck et al., Clin Cancer Res 2006) showed modest PSA effects in small uncontrolled trials but have not been replicated in larger randomised studies^[33].
• General diet and lifestyle changes — Mediterranean-style diet, regular exercise, weight loss, and reduced consumption of red and processed meats are associated with lower prostate cancer mortality in observational studies, but their effect on PSA values specifically is modest and not a substitute for proper diagnostic evaluation^[34].

How to read your PSA result — a practical summary

• A raised PSA on a single test does not mean cancer. The first step is a repeat PSA after controlling for transient factors.
• Use the age-adjusted reference ranges, not the single 4.0 ng/mL cutoff^[5].
• If you are on finasteride or dutasteride, your measured PSA should be doubled for interpretation^[14].
• If sustained elevation is confirmed, a urology referral and multiparametric MRI are the contemporary next steps — not immediate biopsy^[18][19].
• PSMA PET-CT enters the pathway after cancer is confirmed, for staging or recurrence assessment^[23].
• Most "natural" PSA-lowering supplements have weak or no high-quality evidence. The honest approach is investigation, not suppression.